Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafolecimab (IBI306) in Heterozygous Familial Hypercholesterolemia (CREDIT-2)
NCT04179669Phase 3Completed
- Sponsor
- Innovent Biologics
- Start
- Dec 2019
- Primary completion
- Jun 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tafolecimab in heterozygous familial hypercholesterolemia (HeFH) (4 arms), sponsored by Innovent Biologics. Primary endpoint: Percentage of LDL-C decreased from baseline injection at 12 weeks. Started Dec 2019; status: completed.
02
Drugs
tafolecimab
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT04179669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04179669.